Interactive Pipeline
Neurodegenerative DMT Therapeutics & Early Diagnosis Pipeline
First-in-Class Therapeutics
YPD-01
PARIS-PGC-1α
Parkinson's Disease
World's first oral small molecule compound targeting PARIS(ZNF746). BBB penetration ratio 0.50-0.6, bioavailability ~40%. Excellent neuroprotective efficacy demonstrated in multiple animal models (AAV-PARIS, MPTP, α-Synuclein PFF). IND filing Q2 2026, Phase 1 initiation Q3-Q4 2026.
Patent
10-2186761
Status
Ongoing Development
YPD-100
ROS
Parkinson's Disease
Therapeutic candidate targeting reactive oxygen species (ROS) for Parkinson's disease.
Status
Ongoing Development
YND-02
Multi-target (4-target) / Neuroinflammation · Neurogenesis
Alzheimer's & other neurodegenerative diseases
A nature-based single-compound candidate with a four-target complex mechanism, usable either alone or in combination with other therapies. Targets the latest Alzheimer's mechanisms — reducing neuronal inflammation and regenerating neural stem cells — for treatment of neurodegenerative diseases.
Patent
10-2280202
Status
Ongoing Development
YCNS-01
ROS / Mito.
CNS Disorders
Therapeutic candidate for CNS disorders based on mitochondrial function recovery.
Status
Ongoing Development
Early Diagnosis
YPDBM-01
PARIS Early Diagnosis Biomarker
Biomarker
World's first early-diagnosis biomarker for Parkinson's disease. Blood-based, easy to collect, and low-cost — designed to popularize early PD diagnosis.
Applied Technology
Blood-based · High accuracy · Low cost
Patent
10-2120794 / 10-2236421 / 10-2236422
YPDBM-02,03
Additional PARIS Biomarker Candidates
Biomarker
Additional biomarker candidates being validated to strengthen precision selection of the PARIS-PD subtype.
Applied Technology
Multi-marker Validation
YPD-HAT
High-sensitive Autoantibody Test
Diagnosis Kit · For high-throughput precision testing
Early-diagnosis kit for hospitals and screening centers performing high-throughput precision testing. Combines high-speed ELISA with multi-peptide mapping biomarkers for high-sensitivity autoantibody detection.
Applied Technology
High-speed ELISA · Multi peptide mapping Biomarker
YPD-ASK
Anytime Self-test Kit
Diagnosis Kit · Real-time individual self-testing
Rapid self-test kit usable anytime, anywhere. Sandwich ELISA format with multi-biomarker readout enables fast and simple early PD screening for individuals.
Applied Technology
Sandwich ELISA · Multi Biomarker
YPD-01
World-first oral small-molecule PARIS(ZNF746) inhibitor — Precision DMT for Parkinson's Disease
YPD-01 Mechanism of Action
A 4-step mechanism through PARIS inhibition
PARIS Binding
Directly binds to the zinc finger domain of PARIS, blocking its activity
Promoter Release
Inhibits PARIS binding to the PGC-1α promoter, releasing transcriptional repression
Mitochondrial Recovery
Restores PGC-1α expression and normalizes mitochondrial biogenesis and function
Neuroprotection
Prevents dopaminergic neuronal death and improves motor function
YPD-01 Development Status
Final stage preparing for Phase 1 clinical entry
Preclinical Progress
Key Milestones
Market Landscape
Aging-driven Parkinson's market expansion and DMT first-mover opportunity
2024 PD Market Size
Current symptomatic treatments
2030 Projected Market
CAGR 5.5%
First-in-class DMT Potential
New market opportunity
Market Context
- ▸Global PD patients: ~12M in 2024 → ~15M by 2030
- ▸1-2 cases per 100 people aged 60+ · 2.4x higher mortality vs. healthy population
- ▸Current 1st/2nd-gen drugs (L-dopa, Dopamine agonists, COMT/MAO-B) are all symptomatic
- ▸Long-term use limited (within 10 years) · ON/OFF response variability · Unmet medical need persists
Opportunity
Integrated precision medicine-based PD DMT development opens ~$22.2B new market opportunity